Lemzoparlimab Biosimilar – Anti-CD47 mAb – Research Grade

Description of Lemzoparlimab Biosimilar - Anti-CD47 mAb - Research Grade

Introduction

Lemzoparlimab Biosimilar, also known as Anti-CD47 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original anti-CD47 antibody. This antibody is a promising therapeutic target for the treatment of various types of cancer and autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Lemzoparlimab Biosimilar in detail.

Structure of Lemzoparlimab Biosimilar

Lemzoparlimab Biosimilar is a monoclonal antibody that targets CD47, a protein that is overexpressed in many cancer cells and plays a crucial role in immune evasion. This antibody is composed of two heavy chains and two light chains that are connected by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions of both the heavy and light chains are responsible for binding to CD47 and initiating the immune response against cancer cells.

Activity of Lemzoparlimab Biosimilar

Lemzoparlimab Biosimilar works by binding to CD47 on the surface of cancer cells and blocking its interaction with the SIRPα receptor on macrophages. This interaction between CD47 and SIRPα is known to inhibit the phagocytosis of cancer cells by macrophages, allowing the cancer cells to evade the immune system. By blocking this interaction, Lemzoparlimab Biosimilar enhances the phagocytosis of cancer cells by macrophages, leading to their destruction. This antibody also promotes the activation of T cells, which further enhances the immune response against cancer cells.

Potential Applications of Lemzoparlimab Biosimilar

1.

Cancer Treatment

Lemzoparlimab Biosimilar has shown promising results in preclinical studies as a potential treatment for various types of cancer, including acute myeloid leukemia, non-Hodgkin’s lymphoma, and solid tumors such as breast, lung, and ovarian cancer. This antibody has the potential to be used as a monotherapy or in combination with other cancer treatments, such as chemotherapy and radiation therapy. Its ability to enhance the immune response against cancer cells makes it a promising candidate for cancer immunotherapy.

2. Autoimmune Diseases CD47 is also known to play a role in autoimmune diseases, as it is involved in the regulation of immune responses. Lemzoparlimab Biosimilar has shown potential in treating autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. By blocking the interaction between CD47 and SIRPα, this antibody can help regulate the immune response and reduce inflammation in these diseases.

3. Research Grade Antibody Lemzoparlimab Biosimilar is also available as a research grade antibody, which can be used by scientists for various research purposes. This antibody can be used in in vitro and in vivo studies to investigate the role of CD47 in different diseases and to evaluate the efficacy of this antibody in different models.

Conclusion

In conclusion, Lemzoparlimab Biosimilar, also known as Anti-CD47 mAb, is a promising therapeutic target for the treatment of cancer and autoimmune diseases. Its unique mechanism of action, targeting CD47, makes it a potential candidate for cancer immunotherapy. This antibody has shown promising results in preclinical studies and has the potential to be used as a monotherapy or in combination with other treatments. Additionally, its availability as a research grade antibody makes it a valuable tool for scientific research. Further studies and clinical trials are needed to fully understand the potential of Lemzoparlimab Biosimilar as a treatment option for cancer and autoimmune diseases.

Lemzoparlimab Biosimilar - Anti-CD47 mAb binds to CD47 Recombinant Protein (Human) in indirect ELISA Assay

Immobilized CD47 Recombinant Protein (Human) (cat. No.PX-P4083) at 0.5µg/mL (100µL/well) can bind to Lemzoparlimab Biosimilar - Anti-CD47 mAb (cat. No.PX-TA1677) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450